

SALARIUS PHARMACEUTICALS, INC.  
2450 Holcombe Blvd., Suite X  
Houston, Texas 77021

June 21, 2022

**VIA EDGAR**

Division of Corporation Finance  
U.S. Securities and Exchange Commission  
100 F Street, N.E.  
Washington, D.C. 20549

Re: **Salarius Pharmaceuticals, Inc.**  
**Registration Statement on Form S-3 (File No. 333-265535)**  
**Request for Acceleration of Effective Date**

Ladies and Gentlemen:

Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Salarius Pharmaceuticals, Inc., a Delaware corporation, hereby requests that the Securities and Exchange Commission accelerate the effective date of the above-referenced Registration Statement on Form S-3 (File No. 333-265535) and declare the Registration Statement effective as of Thursday, June 23, 2022, at 4:00 p.m., Eastern time, or as soon as practicable thereafter.

Please contact the undersigned at (832) 834-6992, or Nicholas Griffin of Hogan Lovells US LLP at (713) 632-1488 with any questions. Also, please notify Mr. Griffin when this request for acceleration has been granted.

Very truly yours,  
SALARIUS PHARMACEUTICALS, INC.

By: /s/ Mark J. Rosenblum  
Name: Mark J. Rosenblum  
Title: Chief Financial Officer

cc: Nicholas Griffin, *Hogan Lovells US LLP*